Abstract Library

#196 Efficacy and Safety of the Combination Streptozotocin, 5-FU in Endocrine Pancreatic Tumors: A Retrospective Study

Introduction: The combination of Streptozotocin with 5-FU has been used during the past decades in our institution as the first-line treatment in pancreatic NETs with low to moderate proliferation.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Antonodimitrakis P, Skogseid B, Hurtig M, Oberg K, Granberg D,

Keywords: Streptozotocin, 5-FU, endocrine pancreatic tumors, progression-free survival, side effects,

#193 Paraneoplastic Antigen Ma2 Autoantibodies as Specific Blood Biomarkers for Detection of Early Recurrence of Small Intestine Neuroendocrine Tumors

Introduction: Small intestine neuroendocrine tumors (SI-NETs) are rare fatal cancers. Many patients develop metastatis before diagnosis. There is no available curative treatment for patients with metastasis.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Cui T, Hurtig M, Li S, Veronesi G, Essaghir A,

Keywords: Ma2, blood biomarker, ELISA, autoantibody, RFS, sequential immunoprecipitation, immuno-dot-blot,

#20 Paraneoplastic antigen Ma2 (PNMA2) auto-antibodies as biomarkers for early small intestine neuroendocrine tumors detection

Introduction: Small intestine neuroendocrine tumors (NETs) comprise well-differentiated NET (benign carcinoid), well-differentiated neuroendocrine carcinoma (malignant carcinoid) and poorly differentiated neuroendocrine carcinoma (NEC). The majority of NET patients have developed liver metastases at the time of diagnosis and surgery is then seldom curative. Novel predictive, diagnostic and prognostic markers are thus needed to improve our capabilities to diagnose and cure these tumors. We have previously identified six novel marker genes for neuroendocrine tumor cells by using Affymetrix microarrays and advanced bioinformatics. One of this markers, the paraneoplastic antigen Ma2 (PNMA2), which is normally expressed only in nervous tissue, can in the process of carcinogenesis be detected in tumors located outside the nervous system. The finding that Ma2 is expressed in small intestine neuroendocrine primary tumors and their metastases made it interesting to screen whether antibodies against Ma2 are present in the serum of NET patients.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Giandomenico V

Authors: Cui T, Elgue G, Li S, Hurtig M, Veronesi G,

Keywords: Small intestine neuroendocrine tumors, novel diagnostic biomarker, PNMA2, auto-antibodies as serum biomarker.,